Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cell line xenograft experiment

ABSTRACT: Pediatric ALL cell line 380 was injected via tail vein into NSG mice. Triplicate 380 cell samples were also prepared at the timepoint of injection and stored at -80 oC for comparative analysis with CDXs. Mice were euthanized at onset of leukemia symptoms and spleen, bone marrow and liver samples were collected for proteomics analysis.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Dr. Philipp Lange

PROVIDER: MSV000086727 | MassIVE | Wed Jan 20 02:20:00 GMT 2021

SECONDARY ACCESSION(S): PXD023697

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Publications

PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways.

Uzozie Anuli C AC Ergin Enes K EK Rolf Nina N Tsui Janice J Lorentzian Amanda A Weng Samuel S H SSH Nierves Lorenz L Smith Theodore G TG Lim C James CJ Maxwell Christopher A CA Reid Gregor S D GSD Lange Philipp F PF

Journal of experimental & clinical cancer research : CR 20210315 1

<h4>Background</h4>Murine xenografts of pediatric leukemia accurately recapitulate genomic aberrations. How this translates to the functional capacity of cells remains unclear. Here, we studied global protein abundance, phosphorylation, and protein maturation by proteolytic processing in 11 pediatric B- and T- cell ALL patients and 19 corresponding xenografts.<h4>Methods</h4>Xenograft models were generated for each pediatric patient leukemia. Mass spectrometry-based methods were used to investig ...[more]

PMID: 33722259

Similar Datasets

lung metastasis 100% vs 0%

Project description:Lung metastatic potential of the 29 HNSCC was examined with tail vein metastatic assay as described previously. 1 ×10E6 HNSCC cells in a volume of 200 µL were injected into the lateral tail vein using a 30 gauge needle. Eight to 10 mice were prepared for each cell line. Mice were euthanized using carbon dioxide asphyxiation when they lost more than 15% of their pre-injection body weight or at 90 days after cell injection. Necropsy was performed, and lung was harvested. The lungs were then evaluated for the presence of lung metastases and also weighed.

2017-02-09 | GSE67275 | GEO

Preclinical study with a CD40 agonist on patient-derived xenograft mice for the treatment of B-cell acute lymphoblastic leukemia

Project description:To induce leukemia in NOD/SCID/γc−/− (NSG) mice, we injected 10^5 human B-ALL cells, into the tail vein of non-irradiated mice. Two different PDX mice models were studied (PDX-1; #1 and PDX-2; #2). The InVivoMAb anti-human CD40 antibody (BE0189, clone G28.5, BioXCell) was i.v. administrated (CD40) at the dose of 1 mg/kg, the same was done with the recommended isotype (Ig) (BE0083, MOPC-21, BioXCell). We administrated antibodies, at days 15 and 25. At day 35, when mice developed leukemia, B-ALL cells were purified from the BM of PDX-mice, with magnetic beads-conjugated to human CD45 antibodies. Three mice per condition were tested (replicat 1 to 3; mice m1 to m3).

2024-10-10 | PXD047749 | Pride

Bulk RNA-Seq analysis of CD8+ T cells from treatment-naïve matched tumor-bearing lungs and spleens from the HKP1 orthotopic mouse lung adenocarcinoma model

Project description:To investigate how gene expression profiles change in CD8+ T cells based on time, tumor burden, and tissue localization, we orthotopically implanted the mouse lung adenocarcinoma HKP1 cell line expressing luciferase into syngeneic C57BL/6 mice by tail vein injections. Tumor growth was monitored by bioluminescence imaging. A separate cohort of mice received no tumor implantation. At days 7, 17, and 24 post tumor implantation, mice were euthanized and CD8+ T cells sorted from tumor-bearing lungs and spleens, or matched naive lungs and spleens. We then performed gene expression profiling analysis using data obtained from RNA-seq of sorted cells, comparing across time, tumor burden, and tissue localization.

2023-10-19 | GSE218141 | GEO

Comparative gene expression profiling analysis of RNA-seq data for mCherryHigh and DTC populations compared to mCherryLow metastatic populations [mCherry Pops and DTCs]

Project description:To investigate characteristics of the Gstt1high metastatic subppulation in pancreatic cancer, lung metastatic cell line was generated to express mCherry from the Gstt1 endogenous promoter. Mice were injected via tail vein with mixed populations until evidence of metastatic disease, or 5 days after injection for DTC sorting. Upon evidence of metastatic disease, mice were euthanized and lung tissues were digested followed by sorting of mCherry tumor cell populations (top 15-20%) gated on GFP. DTCs were collected 5 days after injection by gating and sorting on GFP. We then performed gene expression profiling analysis using data obtained from RNA-seq comparing mCherryHigh and low populations.

2024-04-01 | GSE232197 | GEO

Targeting low levels of MIF expression as a potential therapeutic strategy for ALS

Project description:CSF was collected from non-transgenic and SOD1-G37R transgenic mice not treated or treated with AAV-PHP.eB-MIF using single tail-vein injection after the disease onset.

2024-05-03 | PXD046619 | Pride

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia

Project description:Purpose: Compare transcriptional changes between drug treated (gilteritinib, TP-0903) and vehicle in acute myeloid leukemia xenografts. Methods: FLT3-ITD+ MOLM13-RES-Luc+ (MOLM13 cells with a D835Y mutation generating a resistant phenotype) AML cells were xenografted into NSG mice. Mice were randomized according to bioluminescence imaging, and treatment of FLT3 tyrosine kinase inhibitor (gilteritinib, 30 mg/kg, once daily for 5 days/week) was started on day 13 post-tail vein injection. At study end point, mice were humanely euthanized and bone marrow was collected. AML cells (human CD45+) were isolated, and ATAC-seq was performed on HiSeq 4000, total RNA. Sequencing reads were aligned and analyzed for differential gene expression of treatment vs vehicle cohorts. Results: The analysis revealed the chromatin accessibility changes induced by gilteritinib in MOLM13-RES AML xenograft model.

2021-07-07 | GSE179421 | GEO

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia (RNA-Seq II)

Project description:Purpose: Compare transcriptional changes between drug treated (gilteritinib, TP-0903) and vehicle in acute myeloid leukemia xenografts. Methods: FLT3-ITD+ MOLM13-Luc+ AML cells were xenografted into NSG mice. Mice were randomized according to bioluminescence imaging, and treatment of FLT3 tyrosine kinase inhibitors (TP-0903, 60 mg/kg, once daily for 5 days/week; gilteritinib, 30 mg/kg, once daily for 5 days/week) was started on day 7 post-tail vein injection. At study end point, mice were humanely euthanized and bone marrow was collected. AML cells (human CD45+) were isolated, and RNA-seq was performed on total RNA. Sequencing reads were aligned and analyzed for differential gene expression of treatment vs vehicle cohorts. Results: The analysis revealed the transcriptional changes induced by TP-0903 or gilteritinib in MOLM13 AML xenograft model.

2021-07-22 | GSE180181 | GEO

Sequencing of neutrophils in peripheral blood of rats injected with Escherichia coli suspension through tail vein

Project description:Control group: 250 g adult male rats injected with normal saline through tail vein; Experimental group: 250 g adult male rats injected with E. coli suspension through a tail vein

2024-06-13 | PXD053096 |

RNA sequencing of CD11b+ mouse bone marrow cells in mice treated with exosomes with or without HDL mimicking nanoparticles

Project description:We report the sequencing of total RNA from CD11b+ mouse bone marrow cells in three groups of C57BL/6 mice: 1) Mice treated with three systemic (tail vein) injections (Days 1, 3, and 5) of phosphate buffered saline (PBS) (pH = 7.4), 2) Mice treated with three tail vein injections (Days 1, 3, and 5) of exosomes derived from enzalutamide resistant CWR-R1 prostate cancer cells (EnzR exosomes), and 3) Mice treated with three tail vein injections of EnzR exosomes (Days 1, 3, and 5) and high-density lipoprotein mimetic nanoparticles (HDL NPs) (Days 0, 2, and 4). Mice were sacrificed on Day 6, when mouse bone marrow was harvested and RNA from CD11b+ cells was obtained. We find that mice treated with EnzR exosome exhibit alteration in the expression of the matricellular protein, thrombospondin-1. Moreover, we find that HDL NP pre-treatment prevented thrombospondin-1 downregulation in mice treated with EnzR exosomes. This is consistent with our published findings that HDL NPs inhibit the uptake of EnzR exosomes by CD11b+ mouse bone marrow cells.

2021-01-06 | GSE158012 | GEO

NRAS hydrodynamic tail vein injection

Project description:NRAS hydrodynamic tail vein injection

| PRJNA892576 | ENA